INDIANAPOLIS -- A study of more than 21,000 average risk patients at 186 sites across the U.S., led by Regenstrief Institute and Indiana University School of Medicine research scientist Thomas ...

Adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) recommendations and overall mortality among adults with colorectal cancer in a multiethnic cohort ...

Two noninvasive screening tests appeared to be effective in detecting colorectal cancer in an average-risk population, two trials suggested. In the BLUE-C trial, a next-generation multi-target stool ...

Financial toxicity of hematologic malignancy therapies: Subjective experience of patients and impact on access to care. Receipt of financial drug assistance for oral targeted therapy among older ...

ST. LOUIS--(BUSINESS WIRE)--Geneoscopy Inc., a life sciences company focused on the development of diagnostic tests for gastrointestinal health, today announced a strategic collaboration with Labcorp ...

An analysis from a large healthcare system shows that nearly half of those prescribed multitarget stool DNA (mt-sDNA) tests for colorectal cancer (CRC) do not complete them, underlining the need for ...

Patients with an average risk for colorectal cancer (CRC) are candidates for noninvasive tests, such as multitarget stool DNA (mtsDNA), whereas those with a higher risk, including those with a family ...

A recent prospective cross-sectional study in Thailand demonstrates that multitarget stool DNA testing is highly sensitive and specific for detecting colorectal cancer (CRC) among Thai individuals.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present modeling data evaluating the ...

A patient who had repeatedly refused routine screening for colorectal cancer (CRC), despite having lost his 80-year-old father to the disease, was again advised to undergo a colonoscopy at age 56. He ...

Exact Sciences is an oncology diagnostics company that has a strong position in stool-based DNA testing for colorectal cancer. The cancer diagnostics market is large, and growing, but blood-based ...

Modeling data show Cologuard PlusTM test delivers highest life-years gained with fewest number of colonoscopies among noninvasive colorectal cancer (CRC) screening strategies “Exact Sciences is ...